Loading…
Compugen Ltd. is projected to rise to $2.80 by 2027, a +19% move from its current price of $2.35. CGEN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $2.29 | $2.35 | $2.42 | +0.02% |
| Aug 4 | $2.26 | $2.35 | $2.44 | +0.04% |
| Aug 5 | $2.24 | $2.35 | $2.47 | +0.06% |
| Aug 6 | $2.23 | $2.35 | $2.48 | +0.08% |
| Aug 7 | $2.21 | $2.35 | $2.50 | +0.10% |
| Aug 8 | $2.20 | $2.35 | $2.52 | +0.13% |
| Aug 9 | $2.19 | $2.35 | $2.53 | +0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.19 | $2.35 | $2.53 | +0.15% |
| Week 2 | $2.13 | $2.36 | $2.61 | +0.29% |
| Week 3 | $2.08 | $2.36 | $2.68 | +0.44% |
| Week 4 | $2.04 | $2.36 | $2.73 | +0.59% |
| Week 5 | $2.01 | $2.37 | $2.79 | +0.74% |
| Week 6 | $1.98 | $2.37 | $2.83 | +0.88% |
| Week 7 | $1.96 | $2.37 | $2.88 | +1.03% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Compugen Ltd. is a clinical-stage therapeutic discovery and development company that engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. Its pipeline includes COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.
Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc.
for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Compugen Ltd. (CGEN) is a healthcare company focused on therapeutic discovery and development. It is currently trading at $2.28, with a market capitalization of $215.65M. The asset holds a global rank of 3556.
The long-term picture shows a path of potential upside, with the forecast indicating rising average prices through 2030, 2040, and 2050: 2030 avg $4.33, 2040 avg $8.51, and 2050 avg $19.30, alongside bullish sentiment in later years.
A major floor 23.3% below — a decisive break under it would weaken the trend.
The nearest floor, 14.5% below — buyers have tended to step in here.
The nearest ceiling, 6.0% above — a clean break opens room to run.
A major ceiling 31.9% above — clearing it would confirm fresh momentum.
Key CGEN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CGEN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.31 | Buy | $2.32 | Buy |
| MA 10 | $2.34 | Buy | $2.33 | Buy |
| MA 20 | $2.36 | Sell | $2.32 | Buy |
| MA 50 | $2.29 | Buy | $2.33 | Buy |
| MA 100 | $2.41 | Sell | $2.29 | Buy |
| MA 200 | $2.08 | Buy | $2.14 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.13 | Neutral |
| Stoch RSI (14) | 39.55 | Neutral |
| CCI (20) | -8.33 | Neutral |
| Williams %R (14) | -56.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -0.42 | Sell |
| Bollinger %B (20,2) | 0.48 | Neutral |
| Stochastic %K (14) | 44.00 | Neutral |
| TRIX (15) | 0.15 | Buy |
| Awesome (5,34) | 0.07 | Buy |
| Ultimate (7,14,28) | 47.97 | Neutral |
| Momentum (10) | -0.02 | Sell |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 2.29 | Buy |
| ADX (14) | 11.85 | Neutral |
| ATR (14) | 0.06 | Info |
The near-term technical picture reflects a nuanced setup. RSI14 is 50, with a SMA50 of $2.35 and a SMA200 of $2.06, indicating a balanced momentum near trend lines. Nearby support sits at $1.96 and resistance at $2.49, suggesting a narrow trading window ahead.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.52 | $2.35 | $2.95 | 0% | Neutral | |
| $2.23 | $2.80 | $3.72 | +19% | Neutral | |
| $2.35 | $3.03 | $4.17 | +29% | Bullish | |
| $2.96 | $3.92 | $5.56 | +67% | Bullish | |
| $3.49 | $4.71 | $6.86 | +101% | Bullish | |
| $3.53 | $4.85 | $7.21 | +106% | Bullish | |
| $3.70 | $5.17 | $7.84 | +120% | Bullish | |
| $3.80 | $5.40 | $8.33 | +130% | Bullish | |
| $4.13 | $5.97 | $9.35 | +154% | Bullish | |
| $5.05 | $7.40 | $11.77 | +215% | Bullish | |
| $6.38 | $10.01 | $16.94 | +326% | Bullish | |
| $12.94 | $22.81 | $42.24 | +871% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.52 | $2.35 | $2.75 | +0.00% |
| September 2026 | $1.98 | $2.34 | $2.85 | -0.40% |
| October 2026 | $2.01 | $2.40 | $2.95 | +2.34% |
| November 2026 | $1.97 | $2.36 | $2.92 | -1.64% |
| December 2026 | $1.96 | $2.36 | $2.95 | +0.28% |
Click any year to see its month-by-month CGEN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CGEN price prediction for 2026 points to an average of $2.35 (low $1.52, high $2.95) — a potential gain of 0% on today's $2.35. Price action looks broadly range-bound.
In 2027, CGEN is projected to trade between $2.23 and $3.72, averaging $2.80 — a potential gain of +19% from today's $2.35. That is up +19% on the projected 2026 average. A consolidation phase looks the most probable path here.
Compugen Ltd.'s 2028 outlook centres on $3.03, within a $2.35 to $4.17 range. That is up +8% on the projected 2027 average. That marks a +29% change versus current levels. Momentum favours further upside here.
By 2029, CGEN could reach as high as $5.56, with a base case around $3.92 and support toward $2.96 — roughly +67% from $2.35. Buyers look set to stay in control over this stretch.
Expect CGEN to range from $3.49 to $6.86 through 2030. The $4.71 average target implies a +101% move from current prices. That is up +20% on the projected 2029 average. Momentum favours further upside here.
The CGEN price prediction for 2031 points to an average of $4.85 (low $3.53, high $7.21) — a potential gain of +106% on today's $2.35. Buyers look set to stay in control over this stretch.
In 2032, CGEN is projected to trade between $3.70 and $7.84, averaging $5.17 — a potential gain of +120% from today's $2.35. That is up +7% on the projected 2031 average. Momentum favours further upside here.
Compugen Ltd.'s 2033 outlook centres on $5.40, within a $3.80 to $8.33 range. That is up +4% on the projected 2032 average. That marks a +130% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, CGEN could reach as high as $9.35, with a base case around $5.97 and support toward $4.13 — roughly +154% from $2.35. Momentum favours further upside here.
Expect CGEN to range from $5.05 to $11.77 through 2035. The $7.40 average target implies a +215% move from current prices. That is up +24% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The CGEN price prediction for 2040 points to an average of $10.01 (low $6.38, high $16.94) — a potential gain of +326% on today's $2.35. Momentum favours further upside here.
In 2050, CGEN is projected to trade between $12.94 and $42.24, averaging $22.81 — a potential gain of +871% from today's $2.35. That is up +128% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CGEN today (≈ 425.531915 CGEN) could be worth
$9,705.64
+$8,705.64 (+871%) by 2050 · US Dollar
Based on the average projected CGEN price of $22.81 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CGENwould be worth at today's price.
$1,000 invested in CGEN on Jul 31, 2025 (≈ 689.65515 CGEN) would be worth
$1,620.69
+$620.69 (+62.1%) today · 1.62× · US Dollar
Based on a CGEN entry price of $1.45 vs. today's $2.35.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.28 | $1,030.7 | +3.1% |
| 1 month ago | $2.13 | $1,103.29 | +10.3% |
| 3 months ago | $2.71 | $867.16 | -13.3% |
| 6 months ago | $1.81 | $1,298.34 | +29.8% |
| 1 year ago | $1.45 | $1,620.69 | +62.1% |
| All time (5.0y) ago | $6.59 | $356.6 | -64.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CGEN forecast.
Our base-case forecast reaches $4.70 around 2030.
Implied market cap at $4.70: $444.55M
Looking across the multi-year forecast, the average price is projected to rise from $2.28 in 2026 to $4.33 in 2030, then to $8.51 by 2040 and $19.30 by 2050. The forecast shows meaningful upside, with ROI of 89.8% in 2030, 273.1% in 2040, and 746.6% in 2050. Sentiment shifts from Neutral in 2026 to Bullish from 2027 onward, aligning with the rising price outlook.
These figures are estimates and not guarantees, and investing carries inherent biotech market risks and company-specific uncertainties.
Tap a question to reveal the answer.
Avg $4.33; min $3.22; max $6.28; ROI 89.8%; sentiment Bullish.
The forecast shows a bullish trajectory from 2027 onward with rising average prices and high long-term ROI (e.g., 89.8% in 2030, up to 746.6% by 2050), but 2026 is Neutral and there are risks inherent to biotech equities.
Yes, the forecast indicates a 2035 max of $10.30, with higher upside in later years (2040 max $14.33; 2050 max $35.55).
Min $1.52; Avg $2.28; Max $2.88; ROI 0; sentiment Neutral.
Min $11.03; Avg $19.30; Max $35.55; ROI 746.6%; sentiment Bullish.
Compugen Ltd. Community Discussion
0Share your Compugen Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.